ArticleVaccine2020
Erythema multiforme, Stevens Johnson syndrome, and toxic epidermal necrolysis reported after vaccination, 1999-2017.
Article in Vaccine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 46 citations in OpenAlex.
- The immunogenicity and safety of adenoviral-based vaccines.Current opinion in allergy and clinical immunology · 2026Review
- Severe cutaneous adverse reaction to amoxicillin-clavulanate: Pediatric toxic epidermal necrolysis in the Gulf: A case report and literature review.International journal of surgery case reports · 2025Article
- Cutaneous Adverse Events Following COVID-19 Vaccination in Japan: A Questionnaire Survey.Cureus · 2025Article
- Global and Regional Burden of Vaccine-Associated Erythema Multiforme and Their Related Vaccines, 1967-2023: An In-Depth Analysis of the World Health Organization Pharmacovigilance Database.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2025Article
- The Prevalence of Stevens-Johnson Syndrome Complications due to Antiepileptic Drug Use: A Systematic Review and Meta-Analysis.International journal of preventive medicine · 2025Review
- Article
- A Compilation of Drug Etiologies of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.Cureus · 2023Review
- Stevens-Johnson Syndrome Following ChAdOx1 nCoV-19 Vaccination (AstraZeneca).Annals of dermatology · 2023Article
- Occurrence of erythema multiforme following COVID-19 vaccination: a review.Clinical and experimental vaccine research · 2023Review
- Urticaria and mimickers of urticaria.Frontiers in allergy · 2023Review
- A case of toxic epidermal necrolysis after ChAdOx1 nCov-19 (AZD1222) vaccination.The Australasian journal of dermatology · 2022Article
- Generalized erythema multiforme-like skin rash following the first dose of COVID-19 vaccine (Pfizer-BioNTech).Journal of the European Academy of Dermatology and Venereology : JEADV · 2022Article
- Case Report: A successful case of toxic epidermal necrolysis treated with plasmapheresis therapy.F1000Research · 2022Article
- Do we miss rare adverse events induced by COVID-19 vaccination?Frontiers in medicine · 2022Review
- Atypical erythema multiforme related to BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine.International journal of dermatology · 2021Article
- Erythema multiforme after CoronaVac vaccination.Journal of the European Academy of Dermatology and Venereology : JEADV · 2021Article
- Erythema Multiforme Major following SARS-CoV-2 vaccine.Clinical case reports · 2021Article
- Current Pharmacogenetic Perspective on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.Frontiers in pharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundSince the last review of vaccine safety surveillance data for erythema multiforme (EM), Stevens Johnson syndrome (SJS), SJS/TEN, and toxic epidermal necrolysis (TEN) (EM/SJS/TEN), over 37 new vaccines have been introduced in the United States. We sought to describe reported EM/SJS/TEN after vaccines during 1999-2017.
methodsWe identified U.S. reports of EM/SJS/TEN received by the Vaccine Adverse Event Reporting System (VAERS) during 1999-2017. We stratified analysis by condition (EM, SJS, or TEN), and analyzed reports by serious or non-serious status, sex, age group, time from vaccination to symptom onset, exposure to known causes of EM/SJS/TEN, and vaccines administered. We used Empirical Bayesian data mining to detect vaccine-AE pairs reported more frequently than expected.
resultsOf 466,027 reports to VAERS during 1999-2017, we identified 984 reports of EM, 89 reports of SJS, 6 reports of SJS/TEN, and 7 reports of TEN. Few reports of EM (9%), and most reports of SJS (52%), SJS/TEN (100%), and TEN (100%) were serious. Overall, 55% of reports described males, 48% described children aged < 4 years; 58% of EM/SJS/TEN occurred ≤ 7 days after vaccination. Few reports (≤5%) described exposure to known causes of EM/SJS/TEN. Overall, childhood vaccines (e.g., combined measles, mumps, and rubella vaccine) were most commonly reported. We identified 6 deaths; 4 were exposed to medications associated with EM/SJS/TEN. EM after smallpox vaccine was reported disproportionately among people aged 19-49 years.
conclusionsEM/SJS/TEN were rarely reported after vaccination; data mining identified a known association between EM and smallpox vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.